HCV Clinical Trial
— HepPEdOfficial title:
National Prisons Hepatitis Education Project: Research Evaluation
Verified date | March 2024 |
Source | Kirby Institute |
Contact | Andrew Lloyd |
Phone | 02 9385 2534 |
a.lloyd[@]unsw.edu.au | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The National Prisons Hepatitis Education Program (HepPEd Program) is a national, prison-based hepatitis C health literacy education program for healthcare providers, correctional officers, and people in prison. The HepPEd Program aims to improve the public health literacy of the prison sector regarding hepatitis C in prisons. The HepPEd: Research Evaluation aims to evaluate the impact of the HepPEd Program on HCV testing and treatment uptake amongst people incarcerated in Australian prisons, as well as changes in knowledge, attitudes, and capabilities of healthcare providers, correctional officers, and people in prison. The study is a controlled before and after study being conducted in 3-6 correctional centres in Australia.
Status | Recruiting |
Enrollment | 3000 |
Est. completion date | December 2024 |
Est. primary completion date | July 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | All healthcare providers, correctional officers, and people in prison at the participating prison sites are anticipated to be exposed to the various HepPEd Program resources during the 3 month education intervention phase. Participating prison sites must meet the following inclusion criteria to be eligible to participate in the study. Participating prison sites must have: - a prisoner population of 400-600 inmates (assumed mean 500); and - an existing prison-based hepatitis service undertaking both HCV testing and treatment. Prisoners must meet the following inclusion criteria to be eligible to participate as peer educators. Prisoners must: - be currently incarcerated in a participating correctional centre; - anticipate being in the participating correctional centre for >12 months; - be considered as capable and willing, and well-respected amongst their peers; and - have approval from custodial authorities to participate as a peer educator. Correctional officers must meet the following inclusion criteria to be eligible to participate as peer champions. Correctional officers must: - be currently working in a participating correctional centre; and - be considered as capable and willing, and well-respected amongst their peers. Prisoners must meet the following inclusion criteria to be eligible to participate in the interview-style survey and dried blood spot (DBS) testing component: 1. be over the age of 18 years; 2. be currently incarcerated in a participating correctional centre; 3. have sufficient English comprehension skills to understand the survey questions; and 4. be willing and able to provide written informed consent. Healthcare providers and correctional officers must meet the following inclusion criteria to be eligible to participate in the survey component: 1) be currently working in a participating correctional centre. |
Country | Name | City | State |
---|---|---|---|
Australia | Risdon Prison Complex | Hobart | Tasmania |
Australia | Capricornia Correctional Centre | Rockhampton | Queensland |
Lead Sponsor | Collaborator |
---|---|
Kirby Institute | Australasian Society for HIV Viral Hepatitis and Sexual Health Medicine (ASHM), Justice health, corrections, and hepatitis and drug-user organisations in each Australian state and territory |
Australia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The change in the proportion of prisoners treated for HCV before and after the education intervention. | This will be measured by calculating the change in HCV treatment rates before and after the education intervention. | 9 months from baseline | |
Secondary | The proportion of prisoners tested for HCV before and after the education intervention. | This will be measured by calculating the change in HCV testing rates before and after the education intervention. | 9 months from baseline | |
Secondary | The health literacy (knowledge, attitudes, and capabilities) amongst target audience groups (healthcare providers, correctional officers, and people in prison) before and after the education intervention. | This will be measured by assessing the change in health literacy before and after the education intervention. | 9 months from baseline | |
Secondary | The acceptability, utility, and impact of the HepPEd Program. | This is measured by surveys, before and after the education intervention. | 9 months from baseline | |
Secondary | The dose, reach, and fidelity of the HepPEd Program. | This is measured by surveys, before and after the education intervention. | 9 months from baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02604017 -
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection
|
Phase 3 | |
Completed |
NCT01221298 -
A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)
|
Phase 2 | |
Recruiting |
NCT05794646 -
Community Intervention to Eliminate HCV Among People Who Use Drugs.
|
N/A | |
Completed |
NCT04971330 -
Access Anti-HCV Assay European Union (EU) Clinical Trial Protocol
|
||
Completed |
NCT02247401 -
Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt
|
Phase 3 | |
Completed |
NCT02833298 -
Post Sustained Virological Response (SVR) Hepatocellular Carcinoma (HCC) Screening
|
N/A | |
Active, not recruiting |
NCT03981445 -
Integrated HIV Prevention and HCV Care for PWID
|
N/A | |
Completed |
NCT02452814 -
Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection
|
N/A | |
Recruiting |
NCT05904470 -
A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV
|
Phase 2 | |
Not yet recruiting |
NCT06316739 -
The Ganchero Intervention for Migrant People Who Inject Drugs From Puerto Rico in New York City
|
N/A | |
Completed |
NCT02116543 -
TD-6450 MAD Study in HCV Infected Subjects
|
Phase 1 | |
Recruiting |
NCT05454579 -
The South-East Asian Transgender Health Cohort
|
||
Active, not recruiting |
NCT03221309 -
Hepatitis C Treatment to Prevent HIV, Initiate Opioid Substitution Therapy, and Reduce Risky Behavior
|
||
Completed |
NCT03801707 -
Utilization of Hepatitis C Positive Kidneys in Negative Recipients
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT03820102 -
Impact of Metabolic Changes and Vitamin D Status on Virological Response in Patients With HCV Infection Treated by DAAs
|
||
Completed |
NCT01074008 -
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072
|
Phase 2 | |
Completed |
NCT05616598 -
Effect of New Oral Treatment for Hepatitis C Virus on Seminal Parameters
|
Phase 2/Phase 3 | |
Recruiting |
NCT05854511 -
Pharmacokinetics, Safety, Efficacy and Acceptability of Daclatasvir Plus Sofosbuvir in HCV-infected Children
|
Phase 3 | |
Completed |
NCT03069001 -
Sofosbuvir and Simeprevir Versus Sofosbuvir and Ribavirin in Treatment of HCV
|
Phase 4 | |
Completed |
NCT01842451 -
A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C
|
Phase 2 |